PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 1, 2019Science Advances126 citationsOpen Access

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

View Full Paper
MTMegan M. TuFLFrancis Y. F. LeeRJRobert T. Jones

Key Points

Key points are not available for this paper at this time.

Abstract

T cell populations in tumors with DDR2 depletion and those treated with dasatinib when either was combined with anti-PD-1 treatment. Our work provides strong scientific rationale for targeting DDR2 in combination with PD-1 inhibitors.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tu et al. (2019) studied this question.

synapsesocial.com/papers/6a0cb78c660334d4fdeb1f2ahttps://doi.org/10.1126/sciadv.aav2437
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Role of discoidin domain receptor 2 in wound healing.2014 · 25 citations
  2. 2ATM and MET kinases are synthetic lethal with nongenotoxic activation of p532012 · 68 citations
  3. 3Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future2015 · 1,457 citations
  4. 4RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome2011 · 23,937 citations
  5. 5A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain.1993 · 181 citations